Alios, based in South San Francisco, and Cambridge, Mass.-based Vertex (NASDAQ: VRTX) said the safety and tolerability studies of ALS-2200 and ALS-2158 will return data in the second quarter of 2012.
Showing posts with label Alios. Show all posts
Showing posts with label Alios. Show all posts
Friday, December 9, 2011
Vertex, Alios start early-stage hepatitis C trials on 2 drugs
Alios, based in South San Francisco, and Cambridge, Mass.-based Vertex (NASDAQ: VRTX) said the safety and tolerability studies of ALS-2200 and ALS-2158 will return data in the second quarter of 2012.
Monday, June 13, 2011
Alios lands $60M in hepatitis C licensing deal with Vertex
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and Alios BioPharma Inc. on Monday announced a licensing agreement, adding two distinct nucleotide analogues to Vertex’s hepatitis C portfolio. The compounds, discovered by Alios and known as ALS-2200 and ALS-2158, are potential treatments of the hepatitis C virus.
As part of the agreement, Vertex will make an up-front payment of $60 million to South San Francisco-based Alios, in exchange for the worldwide rights to ALS-2200 and ALS-2158. Vertex will take on development costs and research funding, as well as up to $715 million in milestone payments if both compounds are approved. Cambridge, Mass.-based Vertex already expects to pay about $35 million in development milestones in 2011.
Alios is also eligible to receive up to $750 million in sales milestones.
As part of the agreement, Vertex will make an up-front payment of $60 million to South San Francisco-based Alios, in exchange for the worldwide rights to ALS-2200 and ALS-2158. Vertex will take on development costs and research funding, as well as up to $715 million in milestone payments if both compounds are approved. Cambridge, Mass.-based Vertex already expects to pay about $35 million in development milestones in 2011.
Alios is also eligible to receive up to $750 million in sales milestones.
Subscribe to:
Posts (Atom)